Pharmicell Co Ltd 005690
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ₩5,160.00
- Day Range
- ₩5,110.00–5,250.00
- 52-Week Range
- ₩4,300.00–8,870.00
- Bid/Ask
- ₩5,200.00 / ₩5,220.00
- Market Cap
- ₩312.02 Bil
- Volume/Avg
- 209,473 / 2.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 184.51
- Price/Sales
- 5.76
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 134
- Website
- http://www.pharmicell.com
Comparables
Valuation
|
Metric
|
005690
|
166480
|
086890
|
|---|---|---|---|
Price/Earnings (Normalized) | 184.51 | — | 62.15 |
Price/Book Value | 3.81 | 17.66 | 3.30 |
Price/Sales | 5.76 | 11.63 | 3.62 |
Price/Cash Flow | 43.95 | — | 9.98 |
Price/Earnings
005690
166480
086890
Financial Strength
|
Metric
|
005690
|
166480
|
086890
|
|---|---|---|---|
Quick Ratio | 4.51 | 0.29 | 0.91 |
Current Ratio | 9.82 | 0.31 | 1.35 |
Interest Coverage | — | −7.66 | 0.33 |
Quick Ratio
005690
166480
086890
Profitability
|
Metric
|
005690
|
166480
|
086890
|
|---|---|---|---|
Return on Assets (Normalized) | 2.56% | −32.27% | −6.06% |
Return on Equity (Normalized) | 3.10% | −124.84% | −14.21% |
Return on Invested Capital (Normalized) | 2.87% | −45.86% | −2.79% |
Return on Assets
005690
166480
086890
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Nhdwslcrc | Dwll | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lccyjtbnc | Wctkkk | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ygyzxpjd | Nrtqgq | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dtrbfdqh | Nyvzxt | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Hwyxvhgz | Bly | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Kcrhxdwss | Zdff | $29.2 Bil | |||
| Moderna Inc
MRNA
| Mqznnppc | Xcy | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Fjbfkdn | Cblfg | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nnqcrxt | Tghpwls | $13.2 Bil | |||
| Incyte Corp
INCY
| Rhptslxw | Nflwxsj | $13.0 Bil |
United States